Home Stock

Stock Research: J. B. Chemicals & Pharmaceuticals

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

J. B. Chemicals & Pharmaceuticals

NSI:JBCHEPHARM INE572A01028
61
  • Value
    42
  • Growth
    75
  • Safety
    Safety
    59
  • Combined
    70
  • Sentiment
    50
  • 360° View
    360° View
    61
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

J.B. Chemicals & Pharmaceuticals Limited is an India-based pharmaceutical company. It specializes in gastroenterology, hypertension, dermatology, nephrology, respiratory, virology, diabetes, and nicotine replacement therapy (NRT), manufacturing pharmaceutical formulations, herbal remedies, and APIs. Brands include Nicardia, Cilacar, Rantac, Metrogyl, and Cilacar-T. The company has a direct presence in Russia and South Africa, with distributor relationships in the United States, Asia, Africa, and Latin America. In the last fiscal year, the company had a market cap of $3005 millions, profits of $292 millions, revenue of $459 millions, and 5517 employees.

more

ANALYSIS: With an Obermatt 360° View of 61 (better than 61% compared with alternatives), overall professional sentiment and financial characteristics for the stock J. B. Chemicals & Pharmaceuticals are above average. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for J. B. Chemicals & Pharmaceuticals. The consolidated Growth Rank has a good rank of 75, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. This means that growth is higher than for 75% of competitors in the same industry. The consolidated Safety Rank at 59 means that the company has a financing structure that is safer than 59% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a good rank of 50, which means that professional investors are more optimistic about the stock than for 50% of alternative investment opportunities. But the consolidated Value Rank is less desirable at 42, meaning that the share price of J. B. Chemicals & Pharmaceuticals is on the higher side compared with indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 58% of alternative stocks in the same industry. ...read more

more
Strongest Rank Price vs. Book (P/B)
Weakest Rank Liquidity
Country Singapore
Industry Pharmaceuticals
Size Medium
Website jbpharma.com
Index
J. B. Chemicals & Pharmaceuticals stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
42 25 23 43
Growth
75 81 85 33
Safety
Safety
59 27 17 100
Sentiment
50 71 76 84
360° View
360° View
61 47 44 91
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
39 87 70 97
Opinions Change
19 14 40 50
Pro Holdings
n/a 68 27 63
Market Pulse
56 86 93 25
Sentiment
50 71 76 84
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
42 25 23 43
Growth
75 81 85 33
Safety Safety
59 27 17 100
Combined
70 27 23 79
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
27 31 27 41
Price vs. Earnings (P/E)
40 33 30 49
Price vs. Book (P/B)
13 24 28 50
Dividend Yield
79 28 45 39
Value
42 25 23 43
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
67 72 70 70
Profit Growth
76 67 78 10
Capital Growth
36 84 19 1
Stock Returns
71 53 89 91
Growth
75 81 85 33
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
89 44 36 84
Refinancing
20 22 28 64
Liquidity
92 44 40 90
Safety Safety
59 27 17 100

Similar Stocks

Discover high‑ranked alternatives to J. B. Chemicals & Pharmaceuticals and broaden your portfolio horizons.

Shionogi

TYO:4507
Country: Japan
Industry: Pharmaceuticals
Size: X-Large
Full Stock Analysis

JOYY

NSQ:JOYY
Country: Singapore
Industry: Interactive Media & Services
Size: Large
Full Stock Analysis

Venture

SES:V03
Country: Singapore
Industry: Electr. Manufacturing Services
Size: Medium
Full Stock Analysis

Kyowa Hakko Kirin

TYO:4151
Country: Japan
Industry: Pharmaceuticals
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This stock offers a high growth opportunity with safe financing and positive sentiment. It is typically expensive (low Value Rank), as investors pay a premium for high performance. It is for growth-focused investors comfortable paying a premium for a stock with strong future momentum.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews